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ABSTRACT
An abstract of the thesis of Collin M. Shaw for the Master of
Science in Biology presented November 9,1998.

Title: Increased glutathione metabolic defense capabilities In
cultured Alzheimer's diseased lymphoblast cell lines.

The hypothesis to be tested states that the pathology of
Alzheimer's disease (AD) involves elevated levels of oxidative
stress, resulting in elevated levels of cellular oxidative defense
mechanisms. If the premise is true, than AD pathologically
afflicted cells should have a higher demand for glutathione (GSH)
as an innate oxidative defense mechanism hence; greater GSH
concentrations, increased GSH resynthesis capabilities, and
increased

levels

of

cystathionine

gamma-lyase

(CNase).

Alzheimer diseased and age matched control lymphoblast cells,
obtained from OHSU's Oregon Brain Aging Study, were cultured,
and GSH biochemistry was subsequently evaluated.
depleted

by exposing cells

to

the

GSH

GSH was

depleting

agent

diethylmaleate (DEM) and the resulting GSH concentrations were
measured. GSH resynthesis was measured after depleting GSH

with DEM, to a level of approximately half base GSH concentration,
then removing the depleting agent, resuspending the cells in fresh
medium (DEM-free), and subsequently measuring GSH levels.
GSH concentrations were measured by HPLC, and all data was
normalized to cellular protein concentration.

Cellular CNase

specific activity levels were measured by adding cytasthionine, the
CNase substrate, and then measuring the amount of cysteine
produced by means of the DTNB assay. The AD cell lines showed
no increase in base levels of GSH as compared to control cell lines.
The AD cell lines showed a statistically significant increase in GSH
resynthesis capabilities and cystathionine gamma-lyase specific
activity levels.

These findings add further weight to the AD

oxidative stress hypothesis, which is based on the premise that the
causative agent of AD pathogenesis is an increase in the level of
cellular free radicals produced.
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ABBREVIATIONS USED

(AD) Alzheimer's disease
(Apo E) Apolipoprotein Epsilon
(APP) Amyloid beta precursor protein
(~-AP)

Beta-Amyloid protein

(BCA) Bicinchoninic acid
(BSA). Bovine Serum Albumin
(CAT) Catalase
(cm) Centimeter
(cDNA) Complimentary DNA
(CNase) Cystathionine gamma-lyase
(COX) Cytochrome c Oxidase
(C02) Carbon Dioxide
(cys-) Cysteine Thiolate ion
(DEM) Diethyl maleate
(ETC) Electron transport chain
(e4) Apolipoprotein E epsilon 4
(FDNB) Fluoro-2, 4-dinitrobenzene
(g) Gravity
(g-GG) Gamma-glutamyl glutamate
(GPX) GSH peroxidase

(GS-) Glutathione Thiolate Ion
(GSH) Glutathione
(GSK3b) Glycogen synthase kinase 3 Beta
(GSSG) Oxidized form of GSH
(GSSG-R) GSH reductase
(GST's) Glutathione transferases
(HNE) E-4-hydroxy-2-nonenal
(HPLC) High Pressure Liquid Chromatography
(KCI) Potassium Chloride
(KOH) Potassium Hydroxide
(KHC03) Potassium Bicarbonate
(MDA) Malondialdehyde
(J.lI) Microliter
(~lmols)

Micromoles

(mM) Millimolar
(J.lM) Micromolar
(J.lg) Microgram
(mg) Milligram
(mtDNA) Mitochondrial DNA
(NaOH) Sodium Hydroxide
(N) Normality
(nDNA) Nuclear DNA

(nM) Nanomoles
(NFT) Neurofibrillary tangle
(OBAS) Oregon Brain Aging Study
(OH 8 dG) 8-hydroxy-2'-deoxyguanosine
(OHSU) Oregon Health Sciences University
(peA) Percloric acid
(PHF) Paired helical filament
(PHF-t) Hyperphosphorylated tau protein
(PLP) Pyridoxal 5'-phosphate
(RNS) Reactive Nitrogen Species
(ROM) Reactive Oxygen Metabolites
(ROS) Reactive Oxygen Species
(RPMI) Roswell Park Memorial Institute
(SOD) Superoxide Dismutase
(SDS) Sodium Dodecyl sulfate
(SP's) Senile plaques
(TBARS) Thiobarbituric acid-reactive products
(TNF) Tumor Necrosis Factor
(TPKI) Tau protein Kinase I
(TPKII) Tau protein Kinase II

INTRODUCTION

Clinically, Alzheimer's disease (AD) is characterized by
gradual progressive intellectual deterioration. Clinical symptoms
begin with a subtle, and poorly recognized, degeneration of
memory. Slowly memory loss becomes more noticeable and will
eventually become incapacitating, resulting in dementia.

Other

common symptoms include confusion, poor judgement, linguistic
difficulties, agitation, withdrawal, and hallucinations.

Some

patients may even develop Parkinsonian symptoms, seizures,
urinary and fecal incontinence, and fluent aphasia. Terminally ill
patients are mute, and may develop flexion contractures.
Pulmonary and urinary tract infections reSUlting in systemic
sepsis, commonly cause death to afflicted AD patients (Morrison
Bogorad,

1993).

Pathologically, AD is characterized by the

neuronal presence of neurofibrillary tangles (NIT's),

senile

plaques (SP's), Hirano bodies, granulovacuo1ar degeneration,
synaptic loss and selective neuronal loss.
In 1907 A10is Alzheimer, a German neuropathologist and
psychiatrist, initially noted AD.

Dr. Alzheimer described the

hallmark pathological findings in a 51 year-old woman, who
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presented a continuing memory loss, ultimately to the state of
dementia.

Upon autopsy of the afflicted patient, Dr. Alzheimer

described the presence of NIT's, a loss of cerebral cortical
neuronal mass, and the presence of numerous SP's (Markesbery,
1997). The contemporary pathologists, of 1907, suggested that
severe arteriosclerosis was at the heart of these pathological
findings.

It was not until the 1960's, when researchers and

clinicians had a better understanding of neurotransmitters and
access to specific cortical maps, that a specific neurological
disease

(a

separate

entity

from

arteriosclerosis)

dubbed

Alzheimer's Disease was recognized. Since the 1980's, advances
in molecular biological approaches have led to the more
pathologically descriptive understanding of the cellular and
molecular processes involved in AD pathogenesis.
(NEUROFIBRILLARY TANGLES)

Neurofibrillary tangles in Alzheimer's diseased brains are
commonly found in the hippocampus, neocortex, and many
subcortical nuclei.

The hippocampus is involved in the

development of short-term memory and the integration of that
information into long term memory. The neocortex is associated
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with higher cognition, and the size of the neocortex is proportional
to increasing evolutionary cognition (Shephard, 1994a).
The NFT's consist of abnormally paired helical filaments
(PHF's), which are composed of hyperphosphorylated tau (PHF-t)
proteins and are laden with small amounts of ubiquitin (Mori,
1987). The tau protein is one of the many microtubule-associated
proteins and is utilized in promoting the stability of axonal
microtubules.

Axonal microtubules function essentially, as

railroad tracks for intra-neuronal and intra-axonal transport
(Shephard, 1994b).

Tau proteins become hyperphosphorylated

throughout the AD pathological process.

The enzymes that

phosphorylate the tau proteins are thought to be tau protein
kinase I (TPK I) and tau protein kinase II (TPK II) (Imahori, 1997).
Sequence analysis of TPK I complimentary-DNA (cDNA) has
provided convincing evidence that the enzyme is actually glycogen
synthase kinase-3-beta (GSK3b) (Ishiguro, 1993).
The enzymatic sequence of tau phosphorylation by TPK I
and II is convoluted. TPK I can only phosphorylate non-native tau
proteins that have been abnormally phosphorylated, but cannot
phosphorylate tau proteins that have not been abnormally
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phosphorylated. TPK II can phosphorylate both native and non
native tau proteins, regardless of whether the protein has
previously been phosphorylated (Imahori, 1997J.

It is theorized

that TPK I and TPK II act in concert to regulate one another.
Once TPK I is activated, the active enzyme converts native tau
proteins into PHF-tau proteins (Imahori, 1997J. What activates
TPK I and TPK II?
protein

(~-AP)

Imahori, et al. theorized that amyloid beta

occurs in neuronal cells before the phosphorylation

of native tau protein is induced (Imahori, 1997J. They tested this
hypothesis by adding 20 flM

~-AP

to primary tissue cultures of

embryonic rat hippocampal cells. After three hours the cells were
stained with anti-TPK I antibody. The results showed that after
the introduction of ~-AP the statistical quantit.y and the activity of
TPK I increased.
introduction of

~-AP,

These results suggest that upon the
the activity of TPK I is induced, leading to

the phosphorylation of PHF into PHF-tau proteins.
researchers also analyzed the survival of

~-AP

versus control cells and found only 10% of the

The

cultured cells

~-AP

cultured cells

survived as compared to control cells. When the same experiment
was repeated, this time with the addition of actinomycin-D and/or
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cyclobexamide to the medium containing the

~-AP,

hippocampal

cell death was prevented. Application of the anti-transcriptional
and anti-translation8l agents suggests that ~-AP induction ofTPK
I activity induced programmed cell death (apoptosis) to occur
within the hippocampal cell culture. The investigators concluded
that hyperphosphorylation was ultimately induced by

~-AP,

which then stimulated oxidative induction (from an unknown
molecular species) of TPK II and ultimately TPK I. This would lead
to a disruption of axonal transportation, and eventually to cell
death by apoptosis.
(BETA-AMYLOID PROTEIN)

Since 1968, there have been direct correlations observed
between the density of SP's found within the brain of post-mortem
Alzheimer's diseased patients and the severity of clinical dementia
presented by those patients prior to death (Perry, 1978). Typical
SP's, averaging some 50 micrometers in diameter, are found
congregated within extracellular neuronal spaces and can be
classified into four types (Iverson, 1995). The four types vary by
morphological characteristics: diffuse, primitive, neuritic, and a
compact structure.

SP's are spherical extracellular lesions that
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were originally identified and classified by the use of silver-based
histological stains. The central deposit of the SP's is composed of
amyloid fibrils, and is surrounded by dystrophic neurites
(dendrites and axon terminals), activated microglia, and reactive
astrocytes (Iverson, 1995).

All four categories of SP's are

distributed predominantly within the cerebral cortex, particularly
the frontotemporal cortex and the hippocampus.
. Neuritic SP's contain a 6-10 nanometer

~-AP,

predominant component of the amyloid fibrils. The

which is the
~-AP

protein

contains 40-43 amino acids and is derived from amyloid beta
precursor protein (APP). The APP is a ubiquitous transmembrane
glycoprotein.

Currently, it is unknown how

involved with senile plaque etiology.

~-AP

becomes

One hypothesis is that

neuritic SP's are formed following neuronal cell death from the
remnants of neurons containing NIT's (Pike, 1993). This theory
suggests that the SP's are the result of neuronal damage. Other
theories suggest that SP deposits are induced by the deposition of
~-AP.

Alzheimer's disease has been linked to a mutation on the

APP sequence or to a mutation on

~-AP

sequence itself (Iverson,

1995) (as described below in AD genetic risk factors). There are
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two

predominant

hypotheses

derivations of SP's. First:
the

APP

cleavage

overproduction of

~-AP

relating

mechanism for producing
insoluble 42 amino acid

mutations

to

results from a point mutation in

mechanics

~-AP.

~-AP

leading

to

the

catabolic

Second: a mutation in the cleavage
~-AP

from APP results in a more

~-AP.

(GENETIC RISK FACTORS)

. Sporadic (non-mendalian) AD and all familial cases of AD
appear to have the same phenotypic pathological and clinical
hallmarks, although genotypically they differ. Alzheimer's disease
can be divided into four main categories based on genetics
(Blacker, 1998 & Dewji, 1996).

Alzheimer's disease associated

with Down's syndrome (trisomy 21), occurs in less than 10/0 of AD
patients. Early onset AD occurs before the age of 65, represents
5% of AD patients, and is associated with three different genetic
mutations. Late onset AD afflicts 10-250/0 of all AD patients and is
associated with a mutation on chromosome 19, resulting in a
mutation of apolipoprotein E. Sporadic AD, occurs in about 75%
of all AD afflicted individuals, and has a variety of etiologies,
including mitochondrial mutations.
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Down's syndrome is caused by an extra (normal) copy of
the APP gene, located on chromosome 21 (Hardy, 1997). Nearly
all persons afflicted with a genetic mutation on chromosome 21,
resulting in Down's Syndrome, will eventually develop cognitive
decline and will inevitably show all the neuropathological
hallmarks of AD by the age of 40 (Brugge, 1994). Both AD and
Down's syndrome show the common etiological pathology of an
increase in the

~-AP

deposition resulting in cellular death.

Early onset familial AD can be divided into three categories,
AD1, AD3, and AD4. Alzheimer's disease 1 afflicts about 10% of
the early onset AD patients and is associated with a mutation on
chromosome 21, which regulates Apolipoprotein, producing an
over abundance of APP.

AD3 is caused by mutations in the

presenilin 1 gene located on chromosome 14 (Schellenberg, 1992).
The functions of presinilin are not known as of yet, but it is
thought to be an ion channel, a G-coupled receptor, or thought to
interact with the metabolism of APP, or

~-AP.

The mutations in

the presinilin genes cause an increased production of insoluble
B-AP resulting in neuronal damage. AD4 is caused by a point
mutation on chromosome 1, specifically at the site of the
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presinilin 2 gene. Again, the mutation on the presinilin 2 gene
results in an overproduction of ~-AP.
Late onset familial AD, categorized as AD2, effects 10-25%
of the AD population and is associated with a mutation on the
apolipoprotein E (Apo E) gene on chromosome 19 (Martinez,
1998). There are three different Apo E gene alleles distributed
throughout the population: Apo E-e2, -e3 and -e4.

A person

inherits one form of the alleles from each parent, resulting in six
possible genotypes.

The Apo E-e4 allele has been theorized to

have a dose related effect when affiliated with AD pathology. It
was found that persons with two Apo E-e4 alleles had a nine-fold
increased risk and an earlier onset distribution of AD than those
with no Apo E-e4 alleles (Corder, 1993). Persons with one Apo E
e4 allele had a three-fold increased risk and a younger age of
onset than patients with no Apo E-e4 alleles.

Currently no

relationship as to how Apo E-e4 effects the pathogenesis of AD is
understood.

Elevated cholesterol and low-density lipoprotein

levels have been associated with the presence of Apo E-e4 alleles
(Kamboh, 1998).
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Sporadic AD represents the majority of AD patients and a
non-mendalian genetic epidemiology can be presumed. Sporadic
AD can be related to head trauma, cigarette smoking (or other
oxidative damaging mechanisms), and environmental factors such
as viruses and/ or bacteria. Many theories also relate a mutated
mitochondrial genome to sporadic AD pathology
Mitochondria are involved in the respiration of individual
cells. , Mitochondria are responsible for the reduction of oxygen to
water and the production of ATP through the employment of a
sequence of proteins know collectively as the electron transport
chain (ETC). Mitochondria carty their own DNA, which codes for
13 polypeptides integral to the ETC and 24 rRNA molecules
utilized in the production of those 13 polypeptides. Mitochondria
are replicated strictly by binary fision, meaning that all the
mitochondria present within an animal or a plant cell have come
directly from the mother's oocyte of that animal or plant cell via
binary fision.
Sporadic AD exhibits protein defects within ETC complex 4,
specifically the cytochrome c oxidase (COX), which is encoded by
the mitochondrial genes COl and C02 (Davis,
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1997).

COX

activity has been reported to be reduced in blood platelets (Parker,
1990), cultured skin fibroblasts (Petersen, 1986), and the brain

tissue of AD patients (Kish, 1992). The ETC mutation gives rise to
an increased number of reactive oxygen metabolites (ROM's)
within the mitochondria.

ROM examples include superoxide

radicals, hydroxyl radicals, and hydrogen peroxide.

Normal

mitochondrion biochemistry results in the discharge of about 2
3% high energy electrons, which ultimately will produce ROM's. A
mutation in the ETC ultimately can lead to an even higher
discharge of high energy electrons, resulting in the increased
production ROM's and consequently to an increase in oxidative
damage.
For any familial or sporadic genetic risk factor classifying
AD, a common theme can be implied: the increase of insoluble

~

AP and/or overall increase in oxidative damage (as described
above).

If AD is a collection of different molecular pathologies

resulting in one common histological presentation, then a
common biochemical pathway resulting from many different
genetic and environmental insults can be inferred.

The most

common form of pathology coexisting with AD is an increase in
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oxidative damage. The brain is relatively vulnerable to oxidative
free radical damage because of its high oxygen consumption rate,
abundant lipid content, and relatively insufficient number of
antioxidant enzymes (Coyle, 1993).
An increase in ~-AP elevates oxidative damage (Behl, 1992).

Yankner and colleagues first showed that

~-AP

fragments were

cytotoxic to cells in 1989. They did this by digesting

~-AP

into

smaller fragments, and applying these digested polypeptides
directly to both primary hippocampal neurons and to clonal
neuronal cell lines.

After the application of digested protein

fragments the researchers noted neuronal cell death (Yankner,
1990). Behl, et al. (1994) tested rat cortical neurons for damage

caused by direct application of ~-AP. These researchers described
that within an hour after the addition of

~-AP

the neuronal cell's

membranous organelles (golgi and mitochondria) began to show
evidence of ultrastructural damage, and/ or deterioration.

The

implication was that free radicals were at the root of neuronal
cellular damage, since ROM's cause membrane damage.

It has

been shown that vitamin E and other lipophilic antioxidants
protected the neuronal cell lines from
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~-AP

toxicity (Behl, 1992).

The damage inflicted on neuronal cells is caused as

~-AP

exerts a

cytotoxic effect on neurons by binding to microglia's mononuclear
phagocyte scavenger receptor A.

This binding stimulates

microglia to produce neurotoxins, such as reactive oxygen species
(ROS), reactive nitrogen species (RNS) , tumor necrosis factor
alpha (TNF-a), and Apo E (Ikeda,

1998).

In addition,

~-AP

stimulates the activation of the complement cascade proteins. All
of these microglial products ultimately lead to neurotoxicity
through inflammation and apoptosis (Ikeda, 1998).

The cellular antioxidant glutathione (GSH) was discovered
in 1888 and acquired the name philothion, which is Greek for
'love-sulfur' (Cooper, 1997). In 1930, the structure of GSH was
determined to be a tripeptide composed of glutamate, cysteine,
and glycine.

The chemical name for GSH is y-Glutamyl

cysteinylglycine. The y-gluatmyl bond connecting glutamate and
cysteine are resistant to the enzymatic cleavage by cellular
peptidases, allowing GSH to be relatively stable in both the
cellular, and the extra-cellular environments. The majority of
cellular GSH is present in the cytosolic compartment while about
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20% of GSH can be found within the mitochondria (Cooper, 1997).
In the mitochondria, GSH serves as an important defense
mechanism against ROM's created from the process of electron
transport oxidative phosphorylation.

Compartmentalization of

GSH pools also occurs in the brain.

Cerebral GSH pools are

segregated in the non-neuronal cells, including the glial cells,
astrocytes, and/or in axons and nerve terminals.
.Glutathione, which is present ubiquitously in plant,
bacterial, and animal cells, plays an essential role in free radical
detoxification.

It does so by cycling between the reduced thiol

form (GSH) and an oxidized form (GSSG) in which two GSH
tripeptides are linked together by a disulfide bond.

The

GSH/GSSG cycling is catalyzed by two enzymes: GSH reductase
(GSSG-R) and GSH peroxidase (GPX). The cycling between the
reduced and oxidized forms allows GSH to react with and
neutralize many harmful molecules enzymatically. Glutathione is
reactive towards free radicals by donating its sulfhydryl (-SH)
hydrogen atom to most carbon, oxygen (e.g. hydrogen peroxide
H2 0 2), and nitrogen free radicals (ROM's), forming GS- (thiolate
ion), which can react with another GS- to form GSSG.
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) GSSG + 2H20

2GSH + H202

Glutathione is the substrate for many enzymes; three of
great significance relative to the buffering effects of GSH are
Glutathione S-transferases (GST) , GSSG-R and GPX.

The

selenium-containing enzyme, GPX enzymatically scavenges toxic
peroxides and other free radicals, neutralizing them by reducing
them with the hydrogen ion from the GSH sulfydryl group, as
described above.
GSH + ROM + GPX

) GS- + ROMH + GPX

GS- + GS-

) GSSG

The oxidation of GSH produces GSSG, then GSSG-R
reduces GSSG, with help of the cofactor NADPH, reproducing two
reduced GSH molecules.
GSSG + GSSG-R + NADPH + H+

-----+)

2GSH + GSSG-R +

NADP+

The GSH sulfhydryl group conjugates to a variety of
acceptor molecules that need to be biologically neutralized. The
sulfhydryl group is involved in nucleophilic reactions; nucleophilic
addition to a double or triple bond, nucleophilic elimination (of a
halide), and nucleophilic displacement. Glutathione transferases

15

are a class of enzymes which catalyze the conjugation of GSH to
electrophilic substances (RX), forming the corresponding GSH S
conjugates (RSG).

These conjugate molecules include many

xenobiotics (such as organophosphates, allylic compounds, and
epoxides) all of which become relatively unreactive and soluble
when combined with GSH.
GSR + RX + GST

------~)

RSG + HX + GST

.When these compounds become neutralized by GSH
conjugation, they are no longer highly electrophilic and hence no
longer toxic to cells. The GSH S-conjugates can thus be efficiently
cleared out of tissues, because of increased solubility and limited
reactivity.
Glutathione synthesis is dependent upon the presence of
limiting cysteine. Intracellular cysteine levels are usually low, due
to the primary sulfhydryl toxicity of cysteine at elevated
concentrations.

Cysteine toxicity is a consequence of cysteine

reactivity with protein mixed disulfides,

alpha-keto acids,

chelation of metals, and many other properties of this highly
reactive amino acid. Cysteine undergoes disulfide exchange with
protein mixed disulfides, causing a denaturation of some protein's
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native states (Reed, 1983).

Cysteine combines with alpha-keto

acids and forms stable crystalline hemithioketals, resulting in
denatured proteins and polypeptides (Cooper, 1997).
Cystathionine gamma-lyase (CNase) is capable of providing
cysteine for cell use by utilizing the sulfur atom of methionine and
the carbon skeleton and amine group of serine, through the
transulfuration pathway.

Methionine enzymatically looses its

gamma methyl group, forming homocysteine. Homocysteine then
condenses serine to form the thioether cystathionine, through the
catalysis of the enzyme cystathionine synthetase. The pyridoxal
5'-phosphate (PLP) dependent enzyme, CNase, enzymatically
cleaves L-cystathionine into alpha-ketobutyrate, ammonia, and L
cysteine.

CHase + PLP + L-Cystathionlne

---~)

CHase + PLP +

alpha-ketobutyrate, ammonia, and L-cystelne
Cystathionine is a thioether containing amino acid with no
known functions, except to serve as an intermediate in the
transulfuration pathway. The transulfuration pathway is a major
source of cysteine when the rate of GSH biosynthesis is high, or
when cysteine concentrations are limiting (Reed, 1995)
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The adult brain normally relies almost exclusively on the
oxidation of glucose to meet its high energy demands. In the
brain, hydrogen peroxide results from oxidative metabolism in the
mitochondria, and from a variety of other sources including the
monoamine oxidases, d-amino acid oxidases, and catacholamine
autoxidation.
Other toxic oxygen species produced systemically and in the
brain include singlet oxygen (1°2), superoxide free radicals (02-),
and peroxides (0 2 2 -) (Brock, 1984).

Chemical activation from

cytochromes and flavins induces 10 2 formation from biologically
ground state triplet oxygen (02)' Singlet oxygen is also chemically
formed by peroxysomal enzyme catalysis. Formed in transiently
small amounts during respiration and from light activation,

°

2-

is

very reactive and can easily cause damage to lipids and other
biochemical components.

Hydrogen peroxide is an example of

0 2 2 - and peroxides are produced by two electron reduction of
ground state 02
Pathologically, the genetic disruptions that occur in AD lead
to an overload of free radicals; some created by
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~-AP

activation of

microglia and/ or the ETC COX mutation, and some created by
normal biological chemistry.
To defend against these oxidative insults, cells have
developed cellular defense systems, which include GSH and the
enzymes catalase and superoxide dismutase. Catalase is limited
to the peroxisomal compartments within cells.

Superoxide

dismutase converts the superoxide anion radical into the less
active but relatively stable species, hydrogen peroxide. Thus the
brunt of the free radical detoxification process, defending against
and neutralizing hydrogen peroxide, is dependent on GSH's
antioxidant capabilities.

(SYNOPSIS OF EXPERIMENTATION)

In these experiments GSH concentration and GSH resynthesis
capabilities in AD afflicted lymphoblasts and non-afflicted age
matched control lymphoblasts were measured and subsequently
evaluated.
continuously

The theory being tested is that if AD cells are
under

increased

oxidative

stress,

then

the

Alzheimer's diseased cell capacity to defend against any oxidative
insult should be greater than the defense capacity of comparable
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non-afflicted control cells.

Control and AD lymphoblasts were

used throughout these experiments because their mitochondria
are the same as the mitochondria of neurological cells (since
direct binary fision from the mother's oocyte's mitochondrial pool,
produces all cellular mitochondria).
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METHODS&MATERIALS
Roswell Park Memorial Institute medium 1640 (RPMI),
Glutamine, Streptomycin and Penicillin, were purchased from
Sigma chemical company, St. Louis, MO. Bovine calf serum was
purchased from Hyclone laboratories, Logan, UT.

Flasks were

purchased from Falcon plastics, Boston, MA. Lymphoblasts from
Alzheimer's diseased patients and lymphoblasts from control
patients were donated from the Oregon Brain Aging Study (OBAS)
at Oregon Health Sciences University (OHSU).

The AD donors

were post mortem histologically confirmed Alzheimer's diseased
positive.

The age matched control cells were obtained from

persons of similar age, sex, lifestyle, geographic area, ethnicity,
and trauma backgrounds by the OBAS. The cell lines that were
investigated are listed below in Table 1.

AD1085, AD864, &

ADl137 represent Alzheimer's diseased cell lines and Co152,
Co166, & Co203 represents lymphoblast cell lines from the
Oregon Brain Aging Study whom were control subjects.
TABLE 1. Lymphoblast ceU lines investigated

Cell Line

Sex of donor

AD 1085
AD 1137
AD 864
Co 152
Co 166
Co 203

Female
Female
Male
Female
Female
Male
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Anchorage independent lymphoblast cell lines were grown
in RPMI 1640 (pH of 7.45) supplemented with 4 mM L-glutamine;
(100 Jlg/ml) streptomycin; (100 units/ml) penicillin G sodium;
and 11 %

bovine calf serum.

The cell lines were individually

maintained in 500 ml and 1000 ml volume Erlenmeyer flasks with
sponge closures. Cell suspensions in the flasks were always kept
below a level of one inch, allowing normal oxygen metabolism to
thrive. Cell suspensions in volume flasks were incubated at 37°C
and a six percent carbon dioxide water saturated atmosphere.
Lymphoblast cultures were diluted on a tri-weekly basis to an
optimal cell density of 1.5 x 106 cells/ml. Cell density was
counted using a Reichert Bright Line hemocytometer and an
Olympus

optical

CK2

lOx

inverted

Phase-contrast

light

microscope.
Medium was routinely changed by centrifuging cellular
suspensions (Beckman TJ-6 centrifuge 5 minutes at 1000 x g),
removing the medium superior to the cell pellet, and then
replacing with fresh medium.

A volume of fresh medium was
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added which was necessary to yield an optimal 1.5 x 106
cells/ml.
Cells were grown for at least two weeks in the medium
before beginning any studies. This allowed the cells to adapt to
the culture conditions.
To prepare for assays, cell density was counted the day
before the assay was to be performed. Cells were centrifuged in
polypropylene centrifuge tubes at 1,000 x g (for 5 minutes) and
resuspended in fresh medium to an optimum cell density of 3 x
106 cells/ml for the aSH depletion and resynthesis assays and 5
x 106 cells/ml for the cystathionase assays. After centrifugation,
cells were pre-incubated in RPMI 1640, and placed in 25 cm2
polystyrene tissue culture flasks. The cells and the flasks were
then positioned on their side, in a 37°C incubator, overnight.
aSH Depletion Assay

Cell density was determined the day of the experiment and
recorded.

Flasks containing cells were removed from the

incubator and gently shaken to evenly distribute all cells.

A

quantity of cell suspension was prepared (13 mls) which would be
adequate for six one ml samples, allowing for one extra ml.
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Protocol; GSH depletion preparation: A one ml sample of
suspension was removed from the flask and added to an
appropriately labeled 1.5 ml microfuge tube. The microfuge tube
was centrifuged at 13,000 x g in a Fisons micro centaur
centrifuge for 20 to 30 seconds.

The supernatant liquid was

removed and discarded with a disposable pipette. Next 500 ,.11 of
10% perchloric acid (PCA) and 15 J.1,1 of 1 J.1,mole / ml gamma
glutamyl glutamate (y-GG) was added to the cells left from
centrifugation. The protocol was repeated twice for each time
allotment. Tops were closed on the now prepared microfuge tubes
were placed in a rack, at room temperature, until the remainder
of the assay was completed.
To the residual cells, remaining in the tissue culture flask,
diethyl maleate (DEM) (DEM 1:10 dilution in DMSO) was added to
a final concentration of 200 mM DEM. The DEM used was 98%
pure.

Addition of the DEM was designated as time zero.

The

tissue culture flasks were then returned to the 37°C incubator. At
time points of 15, 30, 45, 60, and 90 minutes tissue culture
flasks were removed from the incubator, and a one ml sample of
cell suspension was extracted and treated as previously described
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for the GSH depletion preparation.

Duplicate samples were

removed and treated at each time point. The sample microfuge
tubes were placed in a tube rack, at room temperature, for the
duration of the experiment.
PROTEIN ASSAY AND HPLC PREPERATION

From the GSH depletion assay, microfuge tubes containing
AD and control cell lines (immersed in PCA and g-GG) were
centrifuged at 12,000 x g for 20 minutes, at 3°C (Fisons micro
centaur centrifuge).
removed

and

the

After centrifugation, microfuge tubes were
supernatant

was

transferred

to

the

corresponding labeled 4 ml yellow disposable culture tube, and
left uncovered.
A quantity 250 J11 of 30 mM NaOH in 10/0 sodium
dodecylsulfate (SDS) was added to the precipitated protein pellets
in the microfuge tubes.

The microfuge tubes were placed in a

refrigerator at 4°C until the protein assay could be completed.
Yellow disposable culture tubes were utilized in order to
minimize ultra-violet light exposure and inhibit degradation of
susceptible compounds. To each yellow tube containing the cell
supernatant, 50 J11 of 15 mg iodoacetic acid in 1 ml of 0.2 mM

25

meta-cresol purple was added. Then 500 J.lI (added in increments
of 100 J.lI) of 2 normal (N) potassium hydroxide (KOH) in 2.4 N
potassium bicarbonate (KHC03 ) was added to the yellow tubes.
Next, the yellow tubes were placed in the dark (at room
temperature) for more than 2 hours, to allow C02 to escape. After
at least 2 hours, 500 J.lI of 1% (v Iv) fluoro-2,4-dinitrobenzene
(FDNB) in 950/0 ethanol was added to each tube. The tubes were
then 'capped and again placed in the dark (at room temperature)
for at least 6 hours, to allow formation of N-DTNB derivatives for
measurement of GSH by HPLC.
The glutathione concentration was determined using a
method of HPLC (Fariss, 1987). Yellow tube HPLC samples were
centrifuged at 2000 x g for 10 minutes (Beckman TJ-6 centrifuge).
The supernatants were analyzed for GSH, using a Spectra Physics
8700 high-performance liquid chromatograph, equipped with a
LDC UV-III detector and a Hewlett Packard 8390A recording
integrator. The internal standard, y-GG (15 J.lmole/ml), was used
as a reference.

All GSH concentrations were derived using

quantity/ml data relative to the y-GG known standard.
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Cell extract protein concentrations were determined by the
Pierce bicinchoninic acid (BCA) protein assay (Smith, 1985). The
BCA

assay

is

based

on

comparing

unknown

protein

concentrations to known protein concentrations of bovine serum
albumin (BSA) standards. BSA standards prepared were 10, 20,
30, 40, 50, 60, 80, and 100 J..lg/1000 Jll of 1010 SDS in water. A
standard curve was created by measuring the absorbance of the
known BSA standards at a wavelength of 562 nm.

The same

quantity of experimental cell protein extract was measured at 562
nm, the absorbance was noted, and the respective J..lg of protein
per ml was calculated.

Protein assays were performed in

microtiter plates, allowing for multiple samples to be read and
hence greater accuracy. The microplate reader was an Anthos ht

°

II labtech. To micro titer plate wells 1 J..lI of evenly distributed
protein pellet sample along with 200 J..lI of BCA protein reagent
was added.
aSH RESYNTHESIS ASSAY

Cell density was determined the day of the experiment using a
Reichert bright line hemocytometer. Tissue culture flasks were
removed from the incubator and gently shaken to evenly
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distribute the cells. A quantity of cell suspension was prepared
(12 mls) that would be adequate for the GSH reysnthesis assay: 2
one ml samples for the negative time, for time 0 resuspension,
and for resuspension times 20, 50, and 90 minutes post
resuspension.
Protocol; GSH resynthesis preparation: A one ml sample of cell
suspension was removed from the flask and transferred to a 1.5
ml microfuge tube. Duplicate samples were removed at zero time
and for each other time point. The microfuge tubes, labeled with
their appropriate times (t =-35 and -40), were centrifuged at
13,000 x g in a Fisons micro centaur centrifuge for 20 to 30
seconds. The supernatant was removed and discarded, then 500
J.LI of lOOk peA and 15 I.d of 1 Ilmol/J.LI 'Y-GG was added to the cell
pellet.
To the cell suspension remaining in the flask DEM was
added to give a final concentration of 200 mM DEM. The flasks
were then returned to the incubator.
The time necessary to deplete GSH to half base GSH
concentration was determined from the GSH depletion assays.
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For all AD cell lines, GSH depletion time was 35 minutes, and for
control cell lines GSH depletion time was 40 minutes.
At the pre-determined GSH depletion time, duplicate one
ml aliquots were prepared, as previously described for GSH
resynthesis preparation. The residual cell suspension remaining
in the 25 cm2 flask was removed from the flask and transferred to
a polypropylene centrifuge tube. The suspension was centrifuged
at 1000 x g for three minutes in a Beckman model TJ-6
centrifuge. The samples were removed from the centrifuge and the
supernatant liquid was discarded. The cells were then returned
to the 25 cm2 tissue culture flasks and incubated at 37°C, in an
equal amount of RPM!. This was designated as resuspension time
zero.
At time points of 20, 50, and 90 minutes post cell
resuspension, duplicate samples were removed and treated as
previously described, (in "GSH resynthesis protocol") to determine
GSH concentration by HPLC.
Once the GSH resynthesis assay was complete, the
precipitants were saved and assayed for protein concentration as
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previously described. The cell extracts were prepared for HPLC as
previously described.
DTNB CNase ASSAY

The

DTNB

(5-5'-dithio

bis-2-nitrobenzoic

acid)

assay

measures the quantity of product catalyzed by the enzyme CNase.
This is done via colorimetric determination of the quantity of thiyl
containing

cysteine

produced

from

the

added

substrate,

cystathionine (Flavin, 1962 and Hargrove, 1987). The thiyl groups
produced, bind to DTNB and yields para-nitrothiolate, a structure
that highly resonates.
absorbs at 412 nm.

Para-nitrothiolate is yellow and readily
Absorbance was measured, using a LKB

Biochrom Ultrospec II spectrophotometer, and results were
calculated using Beer's Law, an extinction coefficient of 13,600 m
1cm- 1, and an absorbency of 412 nm.

CNase units were then

calculated in mmoles of thiyl containing cysteine produced per
minute per mg of protein.
Prior experiments were conducted, using a variety of cell
concentrations,

in

order

to

determine

what

CNase

cell

concentration would be within the linear slope of the protein
standard curve (5 x 106 cells/ml).

30

Background

thiyl

group

concentrations

(background

control) within the cell were determined by the addition of 200 III
of 10%

SDS to the time zero cell sample.

effectively inhibited all metabolic activity.

Addition of SDS
All other reagents

utilized in the CNase assay were then added to the control
samples (DTNB, L-cystathionine, PLP, and EDTA).

The reagent

DTNB covalently bonded with all background thiol groups,
producing para-nitrothiolate, thus giving the background thiyl
concentration.
To assay the enzyme CNase, the enzymes substrate, L
cytstathionine, was added.

L-cystathionine, added to a final

concentration of 2 mM, was added to AD and control cell lines
suspended in 0.1 M Potassium phosphate buffer (pH 7.35 KCL
added) at time zero along with PLP and EDTA (Flavin, 1962 and
Hargrove, 1987).

PLP was added to a final concentration of 0.1

mM and was utilized because it is a cofactor for the CNase
enzyme. EDTA was added to a fmal concentration of 0.5 mM and
was used as a chelator of unnecessary divalent metals. At 5 and
10 minutes, 200 ~Ll of 100/0 SDS was added to the cells, thus

stopping all metabolic reactions. Ten minutes after the addition
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of SDS, 50 ,.d of 20 mM DTNB (DTNB diluted in 950/0 ethanol) was
added,
Subtracting the control thiol concentrations (time zero
experiments) from the experimental thiol concentrations (enzyme
allowed to catalyze substrate into product for 5 and 10 minutes)
gave the total amount of cysteine produced from the enzyme
CNase. For CNase specific activity, the moles of cysteine per ml,
was divided by J.lg of protein per ml and then divided by time (5
and 10 minutes).
The statistical significance of the results obtained from the
GSH

(depletion and resynthesis)

and CNase assays were

determined by the student's t test. (Arkin, 1970).
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RESULTS

The working hypothesis was that AD lymphoblasts should
have a higher level of GSH, an increased GSH resynthesis
capability after GSH depletion, and an increased activity level of
the enzyme CNase. All of these parameters would be indicative of
an increased oxidative defense capability, as is suggested by AD
pathophysiology.
,The cell lines selected for the study were received from the
OHSU Oregon Brain Aging Study program.

There were three

control lymphoblast cell lines (C-1066, C-152, & C-152) and three
Alzheimer's diseased lymphoblast cell lines (AD-1085, AD-1137, &
AD-864) investigated throughout the experimental process (as
shown in Table 1).
The GSH concentration in control cell lines was analyzed
and the average concentration was calculated to be 0.1547 nmols
GSH/mg of protein. The AD cell lines' base GSH concentration
averaged 0.1342 nmoles GSH/mg of protein (Table 2).

The

standard deviations for AD and control cell GSH concentrations
were 4.06 x 10-2 and 1.34 x 10-2 , respectively. Figure 1 shows a
graphical comparison between the AD and control cells GSH
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concentrations.

Analysis of the mean AD and control GSH

concentration data through statistical analysis, a t value of
0.4097

was

calculated

(n=18):

thus

the

differences

in

concentrations calculated were determined not to be significant,
(p>0.3).
Figures 2 through 4 display the rate of GSH resynthesis for
the AD and control lymphoblast cell lines. The rates of GSH
depletion for both AD and control cell lines are ostensibly parallel,
as shown in Figure 2. The GSH resynthesis data was evaluated
twenty minutes after washing off of DEM and resuspension in
fresh RPMI (Figure 3). The AD cell lines GSH resynthesis mean
slope was 4.225 x 10-4 (nmols GSH/mg of protein/min) and for
the control cell lines the mean slope was 2.583 x 10-4 (Figure 3).
The GSH resynthesis standard deviation for both the AD and
control cell line slope was 1.99 x 10-7 and 0.711 x 10- 7 ,
respectively. A t value was calculated to be 3.29, and therefore
synthesis in AD lines was significantly faster, at P< 0.001. Figure
4 depicts the GSH resynthesis concentration results relative to
the initial GSH concentration. The percentage of GSH relative to
initial was averaged for both the AD and control cell lines, and the
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slope calculated. The AD mean slope was 0.2643 and the control
slope was 0.1703. The standard deviations were 0.1089 for AD
and 0.024 for the control.

Synthesis rates were significantly

different at p<O.OOl.
Figure 5 displays the significant differences of individual
cell lines GSH resynthesis rates. The control cell line Co203 GSH
resynthesis rate was significantly different from that of AD1085
(P<O.OOl) and AD864 (P<0.005).

The Co152 resynthesis data

statistically differed from AD 1085 (P<O.OOl) and AD864 (P<0.005).
Co 166 resynthesis data significantly differed from only AD 1085
(P<O.OOl).

The AD1085 resynthesis data significantly differed

from all five other cell lines (P< 0.001 for all control and ADl137)
(P<0.005

for

significantly

AD864).
differed

The
from

ADl137

AD864

resynthesis

(P<0.005)

and

results
AD1085

(P<O.OOl). AD864 resynthesis results differed from four other cell
lines ( P<0.005 compared to control 203, 152, 166, and AD 1085
and 1137), but did not statistically differ from control 166.
Cystathionase assays for the AD and control cell lines are
displayed in Figure 6 and are in units of moles of thiol containing
cysteine produced/min/mg of cellular protein. The AD cell line
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mean CNase production was calculated to be 2.2079 x 10- 10
(n=18) while 1.426 x 10-10(n=18) was obtained for the control cell
lines. The standard deviation was 4.4866 x 10- 11 and 1.53 x lO
II for the AD and control cell lines, respectively.

A twas

calculated to be 7.824, indicating that CNase specific activity in
AD cell lines was statistically larger than control cell lines
(p<O.OOl).
Figures 7 through 12 represent AD and control cell lines
individual GSH depletion and resynthesis concentrations at time
points of -35 (AD, Fig 10-12), -40 (Control, Fig 7-9), and at times
0, 20, 50, and 90 minutes (for all 6 cell lines). The graphs also
displays the individual standard deviations (SD) for all time
points' GSH concentrations.
Figure 13 displays four different HPLC graphs from the AD
cell line 1085. Retention time (RT) of 38.10 minutes represents
the internal, standard g-GG cellular concentrations, and RT of
42.01 minutes represents GSH cellular concentrations. In Figure
13, four individual HPLC graphs are displayed (-35b, Oa, SOb, and
90a), all at different time points throughout the resynthesis assay.
In Figure 13, Graph -35B represents GSH concentration before
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the addition of DEM. Graph OA represents the GSH concentration
at the time of cellular resuspension in DEM-free medium. Graph
SOB and 90A represents the GSH concentrations at 50 and 90
minutes post-resuspension.
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DISCUSSION

The oxidative stress hypothesis has suggested that reactive
oxygen species may be of significance in the development of AD.
The ultimate question to be investigated is whether AD patients
have an increased sensitivity to oxygen free radicals or an
increased level of free radical formation. An increased sensitivity
to oxygen free radicals would be indicative of a decreased level of
free radical defense mechanisms, such as GSH.

The alternative,

an increased level of free radical formation could be caused by
nuclear and mitochondrial mutations (Davis, 1997) or by external
factors. Intracellular generation of ROM's, such as H202 and 02-'
results in increased transcription of the regulatory and catalytic
subunits of the GSH synthesizing enzyme g-glutamylcysteine
synthetase (Moellering,

1998).

Also noted, ROM's increase the

activity of the transulfuration pathway and the cysteine supplying
enzyme, CNase (Reed, 1995). If the etiological foundation of AD
pathology is based on an increased amount of free radical
formation, then an increased level of free radical defense
mechanism would be expected throughout all afflicted AD cells.
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In these studies, OEM was the GSH depleting agent used
throughout the depletion and resynthesis experiments.

OEM

conjugates to GSH through the enzymatic catalysis of GST's.
GSH nucleophilically attacks OEM's carbon-carbon double bond,
beta to a keto group, the result is a stable molecule, which has
effectively removed GSH.
The results of these experiments showed no statistical
difference between AO and control cell lines for resting GSH
cellular concentration (Figure 1 and Table 2). This result is in
opposition to one of the three parameters investigated throughout
this study. These results may be a phenomenon based on GSH's
high degree of turn over, or on the feed back inhibition of GSH
synthesis. GSH is reported to have a half life of 192 minutes in
the rat liver (Meredith, 1986), 240 minute half life in the kidney
(Scott, 1993), 114 minutes in resting macrophges (Rouzer, 1982),
and 59.5 hours in the brain. (Chang, 1997). With such a quick
and varied GSH turnover rate throughout systemic tissues, GSH
level could be maintained at an appropriate level for defense
against insult. Maintenance of adequate GSH concentrations can
be sustained be recycling GSH and GSSG from an oxidized to a
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reduced form, and by GSH resynthesis from the amino acid
components glycine, glutamate, and cysteine. The quick turnover
rate seem to be an appropriate rational in support of the findings
that GSH levels were not highly elevated in AD afflicted
lymphocytes versus the control lymphocytes tested in vitro. The
second notable process was that feedback inhibition of GSH
synthesis helps to give a rational interpretation for the unelevated
GSH concentrations.
Balazs and Leon determined the levels of GSH in 12 regions
of the brain from AD patients and age matched control patients
(Balazs, 1994). The cells were removed from the AD and control

subjects' brains within 7.3 hours postmortem for AD and 5.8
hours postmortem for controL

These investigators reported no

significant difference in GSH levels in AD brain as compared to
control tissue samples. They also reported no overall difference in
GSH concentrations between the 12 different brain regions. The
investigators used the GSH disulfide reductase DTNB recycling
assay and measured DTNB products using the same procedures
used in the current work.
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The second parameter investigated in this study was the
GSH resynthesis capability in AD cell lines as compared to the
control cell lines.

Figures 2, 3, 4 and 5 display the combined

results of GSH resynthesis experhnents.

Figures 7 through 12

display individual cell lines GSH concentrations at different time
points, and also displays relative standard deviations. Figure 2
shows that while the rates of depletion of GSH between AD and
control

lymphoblats

were

indistinguishably

parallel,

the

resynthesis rates differed. The amount of GSH depletion is also
displayed in Figure 2. Although the goal was to obtain a 50%
depletion

concentration

(as

compared

to

initial

GSH

concentration), there were some variations throughout cell lines.
Sierra-Rivera, et al. noted that the resynthesis rates of GSH were
indistinguishable between GSH depletion concentrations of 20
70%

(Sierra-Rivera,

1994).

Figure 3 represents the GSH

resynthesis data from 20 to 90 minutes after DEM washing and
cellular resuspension in DEM-free medium.

Resynthesis data

was analyzed 20 minutes after resuspension, thus allowing all cell
lines to have comparable resynthesis parameters.

The mean

slopes for all three AD and control slopes were averaged and
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compared with their standard deviations. A significant difference
was calculated differentiating the two mean slopes, with a
probability

of

greater

than

99.9%

(P<0.001).

The

AD

lymphoblasts showed an increased resynthesis capability as
compared to the control cell lines mean resynthesis rate. The AD
mean

resynthesis

slope

was

4.225

x

10-7

nmols

GSH

produced/mg protein/minute, as compared to the control cells
2.583 x 10- 7 .

Figure 4 displays the GSH resynthesis capabilities of AD
and control cell lines relative to the initial GSH concentrations.
The AD and control GSH resynthesis slopes were averaged, and
the mean rates were compared. Again, AD lymphoblasts showed
an elevated capacity to resynthesis GSH as compared to control
cell lines.

Figure 5 displays the significant difference of individual
resynthesis slopes, as obtained from figure three data.

AD cell

lines Ad 1085 and 864 were distinguishable from all other cell
lines, except AD 864 and control 166 were shown to be of no
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significant difference. Adl137 resynthesis data was similar to all
other control cell lines, but the mean resynthesis of all three AD
cell lines did statistically differ from the mean of all the control
cell lines tested (Figures 3 and 4).
GSH is synthesized intracellularly from three free amino
acids in two steps. First, the gamma carboxyl group of glutamate
is activated by ATP and forms an amide with the amino group of
cysteine with the help of the enzyme gamma-glutamyl cysteine
synthetase. The second step involves a similar activation of the
cysteine carboxyl group, by ATP, allowing the dipeptide to
condense with the free amino acid glycine. The second enzyme,
gamma

glutamylcysteine

synthetase,

which

catalyzes

the

condensation of the dipeptide and glycine, is feedback inhibited
by GSH. This feedback inhibition could aid in the rationalization
of the findings that GSH concentration in AD versus control cells
did not statistically differ.

Notably, mean GSH resynthesis

capability was elevated in AD versus control lymphoblast cell
lines.
The limiting reagent in de novo aSH synthesis and
resynthesis is the amino acid cysteine.
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CNase is capable of

providing cysteine through the utilization of methionine's sulfur
atom and serine's carbon skeleton. The transulfuration pathway,
as described in the introduction, provides cysteine when GSH
biosynthesis is at elevated levels and when the cysteine
concentrations are below glutathione's synthesis demands for the
amino acid.

Therefore, cystathionine's capabilities to provide

cysteine in times of high GSH demand are essential too cellular
oxidative defense mechanisms.

When cystathionine is cleaved by

CNase alpha-ketobutyrate, ammonia and the thiolate ion of
cysteine (cys-) are immediately produced. Immediately after lysis,
cys- can perform disulfide exchange with DTNB.

The disulfide

exchange with DTNB produces the highly resonating para
nitrothioloate anion.
wavelength

of 412

spectrophotometer.

This anion is easily detectable at a
nm,

and

can

be

measured

with

a

The CNase experimental assays executed

denoted an increased capability of AD lymphoblast cell lines as
compared to control cell lines to produce

cysteine from

cystathionine (Figure 6). The AD lymphoblast cell lines showed
1.45 times the level of CNase specific activity of control
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lymphoblast cell lines. This data was confirmed with a greater
than 99.9% significant difference (P<O.OOl).
In addition, it is important to note that the control 166 cell
line showed an increased GSH resynthesis capability and an
increased CNase level as compared to the other two control cell
lines (Figures 3, 4 and 5). The explanation for this atypical cell
line can be explained by the possibility that the subject tested is
metabolically in a state of increased oxidative damage.

This

subject may possibly have a potential for AD pathogenesis,
although the donor is still disease free.
Marcus, et al. analyzed neurological tissue samples from
the brain of post-mortem confirmed AD afflicted individuals and
compared those results to tissue samples from age matched
control patients (Marcus, 1998). The investigators analyzed the
activity of oxidative defense enzymes throughout tissue samples
from frontal, temporal, and cerebellar brain regions.
The investigators reported an increase in overall lipid
peroxidation throughout all three tissues, determined by the
production of thiobarbituric acid-reactive products (TBARS).

In

AD tissue samples, the enzyme superoxide dismutase (SOD) was
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reported to be statistically higher in the frontal and temporal
brain regions as compared to control cell tissue.

A significant

decrease in catalase enzymatic activity was reported in the
temporal brain region. In contrast, the investigators reported no
significant difference in the activity of the enzyme GPX.

They

reported a 120/0 increase (AD vs. control) in GPX activity in the
frontal region, almost equal enzyme activity in the temporal
region, and a 28% decrease in GPX activity in the cerebellum
(although none of the data was statistically significant). As stated
above, CAT is limited to the peroxisomal compartments within
cells and SOD only converts the superoxide anion radicals into
hydrogen peroxide, leaving the brunt of hydrogen peroxide to be
neutralized by GPX.

The fact that they reported relatively no

difference in the GPX activity further supports the theory that the
AD etiology stems from an increase in oxidative damage and not
from a decrease in oxidative defense mechanisms, which is
contradictory to their reported theory.
Lovell, et al. determined the levels of the GSH enzymes GPX
and of GSSG-R (Lovell, 1995). GSSG-R reduces the oxidized form
of GSH, GSSG, allowing the two to cycle between the reduced
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thiol form (GSH) and an oxidized form (GSSG) (in which two GSH
tripeptides are linked together by a disulfide bond with the help of
NADPH). The investigators reported a statistical increase in GPX
and GSSG-R activity throughout two regions of AD brain as
compared to control brain tissue samples. This evidence is not
congruent with the previous study, but does support the theory of
increased oxidative defense mechanisms throughout AD tissue.
. E-4-Hydroxy-2-nonenal (HNE) is an electrophilic species
that can covalently modify cellular macromolecules, and is
produced as a by-product of lipid peroxidation. Oxidative stress
causes lipid peroxidation, an autocatalytic process that damages
lipid

containing

structures

and

yields

HNE

along

with

malondialdehyde (MDA). The electrophilic species HNE cross-links
proteins by interacting with cellular nucleophiles, particularly
lysine, histidine, serine, and cysteine residues. The investigators
Montine, et al. investigated HNE's cytotoxicity by adding HNE, an
HNE analog, and MDA to cultured neuroglia (Montine, 1996).
They were investigating the mechanism to which HNE causes cell
death. Their data showed that HNE can cross link cytoskeletal
proteins and is directly cytotoxic to cell cultures.
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However, the

HNE analog and MDA did not cross link proteins and was not
shown to cause cell death.

These investigators theorized that

HNE might be responsible for the disulfide bond-independent
cross linking of the proteins in NFT'S. These experimental results
further support the theory that increased oxidative damage is the
causative agent of AD.

Since HNE is a direct product of lipid

oxidative damage (peroxidation), a mechanism for the production
of cross-linked cytoskeletal protein from peroxidation damage can
be inferred.
Smith, et al. studied overall protein oxidation in AD versus
age matched control brain samples (Smith, 1991). Tissue samples
were taken from the brain fronta1lobe and occipital lobe of each
subject.
measuring

The protein oxidation state was determined by
brain

carbonyl

content.

Excessive

oxidative

modification of proteins in AD patients suggests an increase in
overall oxidative damage, as is suggested in the oxidative stress
hypothesis.

The investigators provided statistically significant

evidence that AD brain samples had an increased amount of
protein oxidation as compared to control tissue samples.
Glutamine synthetase is the enzyme that catalyzes the conversion
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of glutamate to glutamine.

Mixed function oxidation is a site

specific oxidative modification of proteins, occurring near the
metal containing catalytic sites of particular enzymes, as is the
case with glutamine synthetase. These investigators continued to
report a statistical decrease of glutamine synthetase activity in AD
brain samples as compared to control tissue samples.
B-Hydroxy-2'-deoxyguanosine
oxidative DNA damage.

(OHBdO) is a biomarker of

The investigators Morocci, et al. used

OHBdO to differentiate between the DNA oxidation state of
mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) in AD brain
tissue samples as compared to control samples (Morocci, 1994).
They reported a statistical increase in oxidative damage to the
nDNA of AD brain samples as compared to control tissue
samples, with an increase throughout all brain regions studied.
Furthermore, they reported an even higher level of mtDNA
damage in AD as compared to the control brain tissue samples.
The mtDNA damage due to oxidation was drastically higher in AD
versus control samples as compared to the nDNA oxidative
damage. The higher mtDNA versus nDNA' damage supports the

49

theory that an ETC mutation, specifically a COX mutation, has
resulted in elevated levels of oxidative stress in AD pathology.

There is an abundance of data supporting the oxidative
stress hypothesis. The oxidative stress hypothesis is so appealing
as an etiological base for AD because of the fact that an
accumulation of oxidative damage over time could account for the
late life onset and slow progressive nature of the neurological
disorder. Increased amounts of Fe++, AI++, and Hg++ have been
reported in AD brain tissue (Markesbery,

1993), and this is

indicative of increased oxidative damage.

Many parameters

support the increase in oxidative damage theory: increased lipid
peroxidation, increased HNE levels, increased protein and DNA
oxidation, the presence of NFT's, SP's and
As stated in the discussion,

~-AP

~-AP.

elevates oxidative damage

in cells (Behl, 1992), and is capable of generating free radicals by
stimulating microglia to produce neurotoxins such as ROS, RNS,
TNF-a, Apo E.

The microglial activation also stimulates the

complement cascade proteins activation, further leading to cell
death.

Because genetic mutations associated with familial AD
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result in an ultimate increase in insoluble
the

~-AP,

and because of

genetic mutations associated with sporadic AD

(COX

mutation), an overall increase in oxidative insults are resultantly
associated with AD genetic mutations.
The data reported in this study extends evidence which
support the oxidative stress hypothesis. Briefly, In this study, AD
cell lines exhibited ubiquitously higher levels of GSH resynthesis
capabilities and an increase in CNase levels as compared to age
matched control cell lines.

Data accumulated from this study,

taken in context with other experimental data, discussed
throughout this paper, provides considerable evidence that
increased oxidative insult, not decreased defense mechanisms,
are probably at the heart of the Alzheimer's disease pathogenesis.
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CELL TYPE

(n=7)

(n=6)

(n=6)

(n=19)

(n=10)

(n=6)

(GSH) nmoVmg
cell protein

Standard deviation

Co203

0.116997

0.04617

Co166

0.19778

0.037486
I

Co152

0.1496

Ave Co

0.1547

0.0134

Adl085

0.17355

0.023612

Ad 864

0.14733

0.03538

Ad1137

0.1556

0.04254

Ave Ad

0.1342

0.0406

I

0.033223

(n=6)

(n=22)

TABLE 2: Alzheimer (Ad) and Control (Co) resting cellular GSH
concentration, labeled with ralative Standard deviations.
Cellular
GSH concentration was measured by a method of HPLC and all GSH
concentrations
were
normalized
to
cellular
protein
concentrations, as described In "materials and methods'" Results
show no statistical difference between Ad and Co cell lines.

52

0.25

0.2

.....=
~
......

c:>

1-4

~

0.15

....-I
....-I

~

U

CI).

:§
c:>

~

0.1

~

=

tf.l

~

'-'

i

I

i

I

I

I

i

I

Co203

Col66

Co152 Ave Co Adl085 Ad 864 Adl137 Ave Ad

n=7

n=6

n=6

n=19

n=6

n=6

n=6

n=22

CELL TYPE
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Figure 1 3:
Alzheimer's
disease (AD)
cell line 1 085,
high
performance liquid chromatography
(HPLC).
The graphs show an
example of AD 1085 HPLC data results.
Retention time (RT) of
38.10 minutes represents the Internal standard gamma-glutamyl
glutamate (g-GG) within the cellular suspension sample.
The RT of
42.01 minutes represents the quantity of glutathione (GSH) within
the cellular suspension sample.
The quantities were normalized to
cell protein (J.1g of cell protein! ml). Noted on each Individual graph
Is the time of the sample, a-35 represents the sample before the
addition of OEM.
Time 0 represents the sample at the time of
cellular resuspenslon In OEM-free medium, and times of 50 and 90
minutes represents the times post cellular resuspension in OEM-free
medium.
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